Small-molecule APIs: Regulation
Why one inspection letter can shut a supplier out
What this tab covers How it is regulated and what could disrupt supply: hazard classification, rules in the EU, US and India, anti-dumping duties and other trade measures, and supply-risk notes.Hazards
| Classification | UN number | Key risks |
|---|---|---|
| varies by molecule; many are reproductive toxicants, sensitisers or STOT | varies (UN2811, UN3077 or not regulated) | Worker exposure to potent compounds, solvent fires and runaway reactions, and contamination (e.g. NDMA impurities in sartans, 2018). |
Main rules
| Where | Rule | Effect |
|---|---|---|
| US | FDA CGMP and ICH Q7; DMF system; BIOSECURE Act (FY2026 NDAA, Dec 2025) | inspections gate market access; BIOSECURE bars federal contracts tied to listed Chinese biotech firms |
| EU | EU GMP Part II; written confirmation for API imports (Falsified Medicines Directive); CEP; Urban Wastewater Treatment Directive (2024) extended producer responsibility | pharma and cosmetics firms to fund at least 80% of extra wastewater treatment cost |
| China | Environmental inspections and park consolidation | periodic capacity closures |
India
| Rule | Effect |
|---|---|
| Drugs and Cosmetics Act 1940; revised Schedule M GMP (notified Dec 2023; MSME deadline Dec 2025) | raises GMP bar for small API makers |
| PLI scheme for bulk drugs (Rs 6,940 crore, 2020): 41 products, incentives up to 20% of sales for fermentation products | subsidises greenfield KSM and API plants |
| Minimum import price on penicillin G, 6-APA and amoxicillin (DGFT, Jan 2026) | floor on Chinese import prices for one year |
| EIA Notification 2006; bulk drug projects moved from Category A to B2 in 2020 | faster environmental clearance; zero liquid discharge required in many clusters |
Trade measures
- India MIP on three antibiotic inputs (2026)
- DGTR anti-dumping probes on penicillin G, 6-APA, amoxicillin and montelukast from China (Sept 2026)
- US Section 232 investigation on pharmaceuticals and APIs (2025)
Supply risk
High concentration in China for KSMs and fermentation intermediates. India's Department of Pharmaceuticals identified 53 critical APIs where import dependence was highest, which shaped the PLI list. Many generic APIs have only two or three qualified suppliers.